CIBINQO® is a once-daily oral treatment with proven efficacy demonstrated in a large-scale clinical trial program
Pfizer Healthcare Ireland has today announced the availability of the 50 mg, 100 mg and 200 mg doses of CIBINQO® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy, in Ireland.
The availability of abrocitinibin Ireland is based on the results of five clinical studies of more than 2,800 patients including four Phase 3 studies and an ongoing long-term open label extension study. Abrocitinibdemonstrated meaningful improvements across measures of symptom relief and disease control versus placebo. In one trial including an active control arm with dupilumab, which evaluated patients on background topical medicated therapy, abrocitinib200 mg was associated with a greater improvement in itch relief after two weeks than dupilumab.1 Abrocitinib also demonstrated a consistent safety profile across trials, including in a long-term extension study, showing a favorable benefit-risk profile.
Commenting on the announcement, Caitriona McCarthy, Medical Lead I&I, Pfizer Healthcare Ireland said; “Abrocitinib has shown significant efficacy, including relief from the trademark itch symptom, rapid improvements in skin clearance, extent and severity of disease versus placebo, and a favourable risk-benefit profile.”
CIBINQO is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.2
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
View the August IPN magazine here
